Clinical Application and Potential Risk of CAR-T

Abstract

Abstract: Objective To introduce clinical application of chimeric antigen receptor T-cell therapy (CAR-T) and to explore the influencing factors of efficacy and potential risks. Methods Analyze information that affects the efficacy and safety of CAR-T therapy by retrieving literature and related databases at home and aboard. Results CAR-T provides a new treatment for cancer patients, but there are still many problems to be solved in terms of efficacy and safety. Conclusion CAR-T has shown great potential and will bring tumor immunotherapy to a new stage though many challenges ahead.

Key words: CAR-T, cell immunotherapy technology, on-target/off-tumor, cytokine release syndrome

CLC Number:

R994.11

XU Xianxing, YANG Jingwen. Clinical Application and Potential Risk of CAR-T[J]. Chinese Journal of Pharmacovigilance, 2018, 15(9): 555-559.

References

[1] FDA.FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma [EB/OL]. (2017-10-18)[2018-08-31].https://www.fda.gov/NewsEvents/Newsroom/PressAnno-uncements/ucm581216.htm
[2] Ribatti D.The concept of immune surveillance against tumors. The first theories[J]. Oncotarget, 2017, 8(4):7175-7180.
[3] McLaughlin P., Grillo-Lopez A J, Link B K, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program[J]. J Clin Oncol,1998,16(8):2825-2833.
[4] Weiner L M, Surana R, Wang S.Monoclonal antibodies: Versatile platforms for cancer immunotherapy[J]. Nat Rev Immunol,2010,10(5):317-327.
[5] Pegram H J, Lee J C, Hayman E G, et al.Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning[J]. Blood, 2012, 119(18):4133-4141.
[6] Chmielewski M, Hombach A A, Abken H.Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma[J]. Immunol Rev,2014
257(1):83-90.
[7] Chmielewski M, Abken H.TRUCKs: the fourth generation of CARs[J]. Expert Opin Biol Ther,2015,15(8):1145-1154.
[8] Dotti G, Gottschalk S, Savoldo B, et al.Design and development of therapies using chimeric antigen receptor-expressing T cells[J]. Immunol Rev,2014, 257(1):107-126.
[9] Kochenderfer J N, Wilson W H, Janik J E, et al.Eradication of lineage cells and regression in with autologous T cells engineered to recognize CD19[J]. Blood, 2010,116(20):4099-4102.
[10] Kochenderfer J N, Yu Z, Frasheri D, et al.Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells[J]. Blood,2010,116(19):3875-3886.
[11] 夏莉,王月英. 嵌合抗原受体 T 细胞疗法及其在血液肿瘤免疫治疗中的应用[J]. 上海交通大学学报(医学版),2017,37(6): 823-829.
[12] Grupp S A, Kalos M, Barrett D, et al.Chimeric antigen receptor-modifed T cells for acute lymphoid leukemia[J]. N Engl J Med,2013,368(16): 1509-1518.
[13] Maude S L, Frey N, Shaw P A, et al.Chimeric antigen receptor T cells for sustained remissions in leukemia[J]. N Engl J Med,2014,371(16): 1507-1517.
[14] Haso W, Lee D W, Shah N N, et al.Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia[J]. Blood,2013,121(7): 1165-1174.
[15] Giordano Attianese G M, Marin V, Hoyos V, et al. In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by antiCD23 chimeric antigen receptor[J]. Blood,2011,117(18): 4736-4745.
[16] Carpenter R O, Evbuomwan M O, Pittaluga S, et al.B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma[J]. Clin Cancer Res,2013,19(8):2048-2060.
[17] Kenderian S S, Ruella M, Shestova O, et al.CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia[J]. Leukemia,2015,29(8): 1637-1647.
[18] Mardiros A, Dos Santos C, McDonald T, et al. T cells expressing CD123-specifc chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia[J]. Blood,2013,122(18): 3138-3148.
[19] Mihara K, Bhattacharyya J, Kitanaka A, et al.T-cell immunother-apy with a chimeric receptor against CD38 is effective in eliminating myeloma cells[J]. Leukemia,2012,26(2): 365-367.
[20] Crossland D L,Denning W L,Ang S,et al.Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SCLC models[J]. Oncogene,2018, 37(27):3686-3697.
[21] 葛玉凤,韩东晖,吴介恒,等. CAR-T 细胞治疗用于实体瘤的研究进展[J]. 转化医学电子杂志,2017,4(10): 50-55.
[22] Freeman G J,Long A J,Iwai Y,et al.Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation[J].J Exp Med,2000,192(7):1027-1034.
[23] 郑敏,张岚. CAR-T抗肿瘤研究的现状及展望[J]. 山东大学学报(医学版),2016, 54(11):1-6.
[24] Moon E K, Wang L C, Dolfi D V, et al.Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors[J]. Clin Cancer Res,2014,20(16): 4262-4273.
[25] Beavis P A, Slaney C Y, Kershaw M H, et al.Reprogramming the tumor microenvironment to enhance adoptive cellular therapy[J]. Semin Immunol,2016, 28(1):64-72.
[26] Sun M, Shi H, Liu C, et al.Construction and evaluation of a novel humanized HER2-specific chimeric receptor[J]. Breast Cancer Res,2014,16(3):R61.
[27] Sampson J H, Choi B D, Sanchez-Perez L, et al.EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss[J]. Clin Cancer Res,2014,20(4): 972-984.
[28] Zuccolotto G, Fracasso G, Merlo A, et al.PSMA-specific CAR-engineered T cells eradicate disseminated prostate cancer in preclinical models[J]. PloS One,2014, 9(10): e109427.
[29] Duong C P, Westwood J A, Berry L J, et al.Enhancing the specificity of T-cell cultures for adoptive immunotherapy of cancer[J].Immunotherapy,2011,3(1):33-48.
[30] Hegde M, Corder A, Chow K K, et al.Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma[J]. Mol Ther,2013,21(11): 2087-2101.
[31] Grada Z, Hegde M, Byrd T, et al.TanCAR: A novel bispecific chimeric antigen receptor for cancer immunotherapy[J]. Mol Ther Nucleic Acids,2013,2(7): e105.
[32] Hegde M, Mukherjee M, Grada Z, et al.Tandem CAR T cells targeting HER2 and IL13Ralpha2 mitigate tumor antigen escape[J]. J Clin Invest, 2016, 126(8):3036-3052.
[33] Kulemzin S V, Kuznetsova V V, Mamonkin M, et al.CAR T-Cell Therapy: Balance of Efficacy and Safety[J]. Mol Biol (Mosk),2017,51(2): 274-287.
[34] Hinrichs C S, Borman Z A, Gattinoni L, et al.Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy[J]. Blood,2011,117(3):808-814.
[35] Wang X, Popplewell L L, Wagner J R, et al.Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL[J]. Blood,2016,127(24):2980-2990.
[36] Xu Y, Zhang M, Ramos C A, et al.Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15[J]. Blood,2014,123(24):3750-3759.
[37] Gargett T, Brown M P.Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2[J]. Cytotherapy,2015,17(4):487-495.
[38] Craddock J A, Lu A, Bear A, et al.Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b[J]. Immunother,2010,33(8):780-788.
[39] Kershaw M H, Westwood J A, Darcy P K.Gene-engineered T cells for cancer therapy[J]. Nat Rev Cancer,2013,13(8): 525-541.
[40] Hinrichs C S, Restifo N P.Reassessing target antigens for adoptive T-cell therapy[J]. Nat Biotechnol,2013,31(11): 999-1008.
[41] Norelli M, Casucci M, Bonini C, et al.Clinical pharmacology of CAR-T cells: Linking cellular pharmacodynamics to pharmacok0inetics and antitumor effects[J]. Biochim Biophys Acta,2016,1865(1): 90-100.
[42] Pule M A, Savoldo B, Myers G D, et al.Virus-specific T cells engineered to coexpress tumor-specific receptors: Persistence and antitumor activity in individuals with neuroblastoma[J]. Nat Med,2008,14(11): 1264-1270.
[43] Maude S L, Frey N, Shaw P A, et al.Chimeric antigen receptor T cells for sustained remissions in leukemia[J]. N Engl J Med,2014,371(16):1507-1517.
[44] Hoyos V, Savoldo B, Quintarelli C, et al.Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety[J]. Leukemia,2010,24(6): 1160-1170.
[45] Pegram H J, Lee J C, Hayman E G, et al.Tumor targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning[J]. Blood,2012,119(18): 4133-4141.
[46] Markley J C, Sadelain M.IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cellmediated rejection of systemic lymphoma in immunodeficient mice[J]. Blood,2010,115(17): 3508-3519.
[47] Pagel J M,West H. Chimeric Antigen Receptor (CAR) T-Cell Therapy[J]. JAMA Oncol,2017, 3(11):1595.
[48] Casucci M, Hawkins R E, Dotti G, et al.Overcoming the toxicity hurdles of genetically targeted T cells[J]. Cancer Immunol. Immu-nother,2015, 64(1):123-130.
[49] Dotti G, Gottschalk S, Savoldo B, et al.Design and development of therapies using chimeric antigen receptor-expressing T cells[J]. Immunol Rev,2014,257(1): 107-126.
[50] Morgan R A, Yang J C, Kitano M, et al.Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2[J]. Mol Ther,2010,18(4): 843-851.
[51] Lamers C H, Sleijfer S, van Steenbergen S, et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: Clinical evaluation and management of on-target toxicity[J]. Mol Ther,2013,21(4): 904-912.
[52] Lee D W, Kochenderfer J N, Stetler-Stevenson M, et al.T cells expressing CD19 chimeric antigen receptors for acute lymphobla-stic leukaemia in children and young adults: Aphase 1 dose-escalation trial[J]. Lancet,2015,385(9967): 517-528.
[53] Minagawa K, Zhou X, Mineishi S, et al.Seatbelts in CAR therapy: How safe are CARS?[J]. Pharmaceuticals (Basel),2015,8(2): 230-249.
[54] Berger C, Sommermeyer D, Hudecek M, et al.Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells[J]. Cancer Immunol Res,2015,3(2): 206-216.
[55] Maus M V, Grupp S A, Porter D L, et al.Antibody-modified T cells: CARs take the front seat for hematologic malignancies[J]. Blood,2014,123(17): 2625-2635.
[56] Davila M L, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia[J]. Sci Transl Med,2014,6(224): 224ra25.
[57] Barrett D M, Teachey D T, Grupp S A.Toxicity management for patients receiving novel T-cell engaging therapies[J]. Curr Opin Pediatr,2014, 26(1): 43-49.
[58] Mei H, Jiang H, Wu Y,et al.Neurological toxicities and coagulation disorders in the cytokine release syndrome during CAR-T therapy[J]. Br J Haematol,2018,181(5):689-692.
[59] Hu Y, Sun J, Wu Z, et al.Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy[J]. J Hematol Oncol, 2016,9(1):70.
[60] 李军,陈雄波,董坚. CAR-T细胞治疗在血液肿瘤中的临床研究[J]. 生物产业技术, 2017,5(9):27-32.
[61] thestreet. Juno Therapeutics CAR-T Study Halts Following Additional Patient Deaths[EB/OL]. (2016-11-23)[2018-08-31].https://www.thestreet.com/story/13903738/1/juno-therapeutics-car-t-study-halts-following-another-additional-patient-death.html.
[62] Porter D L, Hwang W T, Frey N V, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia[J]. Sci Transl Med, 2015, 7(303): 303ra139.
[63] 张艺瀚. CAR-T 技术的研究发展及现状[J]. 世界最新医学信息文摘, 2018,18(14):31-32.
[64] CFDA. 总局关于发布细胞治疗产品研究与评价技术指导原则的通告(2017年第216号)[EB/OL].(2017-12-22)[ 2018-08-31].
http://samr.cfda.gov.cn/WS01/CL0087/220082.html.
[65] 高建超,高晨燕.嵌合抗原受体基因修饰T细胞早期临床试验的探讨[J].中国药物警戒,2017,14(10):611-621.